AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] REGENXBIO Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

UK-based M&G Plc, through certain wholly owned subsidiaries, has filed a Schedule 13G indicating it now beneficially owns 1,835,681 shares of Spirit Aviation Holdings, Inc. common stock (CUSIP 84863V101). The position represents 7.09 % of the outstanding shares and is held with sole voting and dispositive power; no shares are held jointly. The filing is made under Rule 13d-1(b), classifying M&G as a parent holding company (HC). The shares are held in the ordinary course of business for investment vehicles managed by M&G affiliates, and the filer expressly disclaims any intent to influence control of the issuer. Signature by Regulatory Reporting Technical Manager Tamara Postoj is dated 08 Aug 2025.

M&G Plc, con sede nel Regno Unito, tramite alcune filiali interamente controllate, ha presentato un Schedule 13G indicando di detenere ora beneficiariamente 1.835.681 azioni ordinarie di Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La posizione rappresenta il 7,09% delle azioni in circolazione ed è detenuta con pieno potere di voto e decisionale; nessuna azione è detenuta congiuntamente. La comunicazione è stata effettuata ai sensi della Regola 13d-1(b), classificando M&G come società madre (HC). Le azioni sono detenute nell'ambito ordinario delle attività per veicoli di investimento gestiti da affiliate di M&G, e il dichiarante esclude espressamente qualsiasi intento di influenzare il controllo dell'emittente. La firma del Responsabile Tecnico per la Segnalazione Regolamentare Tamara Postoj è datata 08 agosto 2025.

M&G Plc, con sede en el Reino Unido, a través de ciertas subsidiarias de propiedad total, ha presentado un Schedule 13G indicando que ahora posee beneficiosamente 1,835,681 acciones ordinarias de Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La posición representa el 7,09% de las acciones en circulación y se mantiene con poder exclusivo de voto y disposición; no hay acciones en copropiedad. La presentación se realiza bajo la Regla 13d-1(b), clasificando a M&G como una empresa matriz (HC). Las acciones se mantienen en el curso ordinario de negocios para vehículos de inversión gestionados por afiliados de M&G, y el declarante niega expresamente cualquier intención de influir en el control del emisor. La firma de la Gerente Técnica de Reportes Regulatorios, Tamara Postoj, está fechada el 08 de agosto de 2025.

ì˜êµ­ì—� 본사ë¥� ë‘� M&G PlcëŠ� ì „ì•¡ ì¶œìž ìžíšŒì‚¬ë¥¼ 통해 Spirit Aviation Holdings, Inc. 보통ì£�(CUSIP 84863V101) 1,835,681주를 실질ì ìœ¼ë¡� 보유하고 있ìŒì� 나타내는 Schedule 13Gë¥� 제출했습니다. ì� ì§€ë¶„ì€ ì „ì²´ 발행 주ì‹ì� 7.09%ì—� 해당하며, ë‹¨ë… ì˜ê²°ê¶� ë°� 처분ê¶�ì� 가지ê³� 있습니다; ê³µë™ ë³´ìœ  주ì‹ì€ 없습니다. ì� ì œì¶œì€ Rule 13d-1(b)ì—� ë”°ë¼ ì´ë£¨ì–´ì¡Œìœ¼ë©°, M&Gë¥� 모회ì‚�(HC)ë¡� 분류합니ë‹�. 주ì‹ì€ M&G 계열사가 관리하ëŠ� íˆ¬ìž ìˆ˜ë‹¨ì� ì •ìƒì ì¸ 사업 과정ì—서 보유ë˜ê³  있으ë©�, 제출ìžëŠ” ë°œí–‰ì‚¬ì˜ ì§€ë°°ê¶Œì—� ì˜í–¥ì� 미칠 ì˜ë„ê°€ ì—†ìŒì� 명시ì ìœ¼ë¡� ë¶€ì¸í•©ë‹ˆë‹¤. 규제 ë³´ê³  기술 ê´€ë¦¬ìž íƒ€ë§ˆë¼ í¬ìŠ¤í† ì´(Tamara Postoj)ì� ì„œëª…ì€ 2025ë…� 8ì›� 8ì¼ìžìž…니ë‹�.

M&G Plc, basé au Royaume-Uni, par l'intermédiaire de certaines filiales entièrement détenues, a déposé un Schedule 13G indiquant qu'il détient désormais bénéficiairement 1 835 681 actions ordinaires de Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La position représente 7,09 % des actions en circulation et est détenue avec pouvoir exclusif de vote et de disposition ; aucune action n'est détenue conjointement. Le dépôt est effectué en vertu de la règle 13d-1(b), classant M&G en tant que société mère (HC). Les actions sont détenues dans le cadre normal des activités pour des véhicules d'investissement gérés par des affiliés de M&G, et le déclarant décline expressément toute intention d'influencer le contrôle de l'émetteur. La signature de la Responsable Technique des Rapports Réglementaires, Tamara Postoj, est datée du 8 août 2025.

Das im Vereinigten Königreich ansässige M&G Plc hat über bestimmte vollständig im Eigentum befindliche Tochtergesellschaften eine Schedule 13G eingereicht, die angibt, dass es nun wirtschaftlich 1.835.681 Aktien der Stammaktien von Spirit Aviation Holdings, Inc. (CUSIP 84863V101) besitzt. Die Position entspricht 7,09% der ausstehenden Aktien und wird mit alleinigem Stimm- und Verfügungsrecht gehalten; keine Aktien werden gemeinsam gehalten. Die Meldung erfolgt gemäß Regel 13d-1(b) und klassifiziert M&G als Mutterholdinggesellschaft (HC). Die Aktien werden im gewöhnlichen Geschäftsverlauf für von M&G-Verbundenen verwaltete Investmentvehikel gehalten, und der Melder weist ausdrücklich jegliche Absicht zurück, die Kontrolle des Emittenten zu beeinflussen. Die Unterschrift der Regulatory Reporting Technical Managerin Tamara Postoj ist auf den 08. August 2025 datiert.

Positive
  • Institutional confidence: A well-known UK asset manager now controls 7.09 % of outstanding shares, potentially supporting trading liquidity and market visibility.
Negative
  • None.

Insights

TL;DR: M&G declares a 7.1 % passive stake in Spirit Aviation; neutral but signals institutional interest.

The filing shows M&G Plc has crossed the 5 % reporting threshold with a 1.84 M-share position, giving it sole voting and disposal rights. Because the Schedule 13G is filed under Rule 13d-1(b) and includes a certification of passive intent, the stake appears non-activist. While added institutional ownership can support liquidity and perceived confidence, there is no immediate governance or strategic impact disclosed. Overall, the development is informational rather than transformative for valuation or control dynamics.

M&G Plc, con sede nel Regno Unito, tramite alcune filiali interamente controllate, ha presentato un Schedule 13G indicando di detenere ora beneficiariamente 1.835.681 azioni ordinarie di Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La posizione rappresenta il 7,09% delle azioni in circolazione ed è detenuta con pieno potere di voto e decisionale; nessuna azione è detenuta congiuntamente. La comunicazione è stata effettuata ai sensi della Regola 13d-1(b), classificando M&G come società madre (HC). Le azioni sono detenute nell'ambito ordinario delle attività per veicoli di investimento gestiti da affiliate di M&G, e il dichiarante esclude espressamente qualsiasi intento di influenzare il controllo dell'emittente. La firma del Responsabile Tecnico per la Segnalazione Regolamentare Tamara Postoj è datata 08 agosto 2025.

M&G Plc, con sede en el Reino Unido, a través de ciertas subsidiarias de propiedad total, ha presentado un Schedule 13G indicando que ahora posee beneficiosamente 1,835,681 acciones ordinarias de Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La posición representa el 7,09% de las acciones en circulación y se mantiene con poder exclusivo de voto y disposición; no hay acciones en copropiedad. La presentación se realiza bajo la Regla 13d-1(b), clasificando a M&G como una empresa matriz (HC). Las acciones se mantienen en el curso ordinario de negocios para vehículos de inversión gestionados por afiliados de M&G, y el declarante niega expresamente cualquier intención de influir en el control del emisor. La firma de la Gerente Técnica de Reportes Regulatorios, Tamara Postoj, está fechada el 08 de agosto de 2025.

ì˜êµ­ì—� 본사ë¥� ë‘� M&G PlcëŠ� ì „ì•¡ ì¶œìž ìžíšŒì‚¬ë¥¼ 통해 Spirit Aviation Holdings, Inc. 보통ì£�(CUSIP 84863V101) 1,835,681주를 실질ì ìœ¼ë¡� 보유하고 있ìŒì� 나타내는 Schedule 13Gë¥� 제출했습니다. ì� ì§€ë¶„ì€ ì „ì²´ 발행 주ì‹ì� 7.09%ì—� 해당하며, ë‹¨ë… ì˜ê²°ê¶� ë°� 처분ê¶�ì� 가지ê³� 있습니다; ê³µë™ ë³´ìœ  주ì‹ì€ 없습니다. ì� ì œì¶œì€ Rule 13d-1(b)ì—� ë”°ë¼ ì´ë£¨ì–´ì¡Œìœ¼ë©°, M&Gë¥� 모회ì‚�(HC)ë¡� 분류합니ë‹�. 주ì‹ì€ M&G 계열사가 관리하ëŠ� íˆ¬ìž ìˆ˜ë‹¨ì� ì •ìƒì ì¸ 사업 과정ì—서 보유ë˜ê³  있으ë©�, 제출ìžëŠ” ë°œí–‰ì‚¬ì˜ ì§€ë°°ê¶Œì—� ì˜í–¥ì� 미칠 ì˜ë„ê°€ ì—†ìŒì� 명시ì ìœ¼ë¡� ë¶€ì¸í•©ë‹ˆë‹¤. 규제 ë³´ê³  기술 ê´€ë¦¬ìž íƒ€ë§ˆë¼ í¬ìŠ¤í† ì´(Tamara Postoj)ì� ì„œëª…ì€ 2025ë…� 8ì›� 8ì¼ìžìž…니ë‹�.

M&G Plc, basé au Royaume-Uni, par l'intermédiaire de certaines filiales entièrement détenues, a déposé un Schedule 13G indiquant qu'il détient désormais bénéficiairement 1 835 681 actions ordinaires de Spirit Aviation Holdings, Inc. (CUSIP 84863V101). La position représente 7,09 % des actions en circulation et est détenue avec pouvoir exclusif de vote et de disposition ; aucune action n'est détenue conjointement. Le dépôt est effectué en vertu de la règle 13d-1(b), classant M&G en tant que société mère (HC). Les actions sont détenues dans le cadre normal des activités pour des véhicules d'investissement gérés par des affiliés de M&G, et le déclarant décline expressément toute intention d'influencer le contrôle de l'émetteur. La signature de la Responsable Technique des Rapports Réglementaires, Tamara Postoj, est datée du 8 août 2025.

Das im Vereinigten Königreich ansässige M&G Plc hat über bestimmte vollständig im Eigentum befindliche Tochtergesellschaften eine Schedule 13G eingereicht, die angibt, dass es nun wirtschaftlich 1.835.681 Aktien der Stammaktien von Spirit Aviation Holdings, Inc. (CUSIP 84863V101) besitzt. Die Position entspricht 7,09% der ausstehenden Aktien und wird mit alleinigem Stimm- und Verfügungsrecht gehalten; keine Aktien werden gemeinsam gehalten. Die Meldung erfolgt gemäß Regel 13d-1(b) und klassifiziert M&G als Mutterholdinggesellschaft (HC). Die Aktien werden im gewöhnlichen Geschäftsverlauf für von M&G-Verbundenen verwaltete Investmentvehikel gehalten, und der Melder weist ausdrücklich jegliche Absicht zurück, die Kontrolle des Emittenten zu beeinflussen. Die Unterschrift der Regulatory Reporting Technical Managerin Tamara Postoj ist auf den 08. August 2025 datiert.

0001590877false00015908772025-08-052025-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2025

 

 

REGENXBIO Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37553

47-1851754

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

9804 Medical Center Drive

 

Rockville, Maryland

 

20850

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (240) 552-8181

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

RGNX

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01. Entry into a Material Definitive Agreement.

Amendment to License Agreement with AbbVie

On August 5, 2025, REGENXBIO Inc. (the “Company”) and AbbVie Global Enterprises Ltd. (“AbbVie”), a subsidiary of AbbVie Inc., entered into a First Amendment (the “Amendment”) to the Collaboration and License Agreement, dated as of September 10, 2021 (the “Collaboration Agreement”) by and between the Company and AbbVie. The Amendment modifies the development plan and related milestone structure for the diabetic retinopathy (“DR”) program and adds an additional AbbVie-led investment to support the subretinal wet age-related macular degeneration (“wAMD”) program.

Under the Amendment, the Company will conduct the first registration enabling trial for DR suprachoroidal (“SCS”) treatment as a combined Phase IIb/III trial performed in two parts (Part 1 and Part 2), and AbbVie will conduct the second registration enabling trial as a separate, standalone Phase III trial. In lieu of the $200 million milestone due under the Collaboration Agreement upon first patient dosed in the first registration enabling trial for DR SCS treatment, AbbVie will pay the Company $100 million upon first patient dosed in the Phase IIb/III trial for DR SCS treatment and an additional $100 million upon first patient dosed in the subsequent Phase III trial under the Amendment. AbbVie will also lead a new Phase IIIb randomized controlled study (the “ACHIEVE Study”) to assess the injection burden, adverse events, change in disease activity, and long-term preservation of visual acuity of surabgene lomparvovec (sura-vec, ABBV-RGX-314) in adult participants with neovascular AMD. In exchange for AbbVie covering all the ACHIEVE Study costs, the Company will pay for its costs to conduct Part 1 of the Phase IIb/III SCS DR Study.

Item 2.02. Results of Operations and Financial Condition.

On August 7, 2025, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8‑K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

The Company and AbbVie Inc. issued a joint press release on August 7, 2025, announcing the entry into the Amendment, a copy of which is attached hereto as Exhibit 99.2 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press release dated August 7, 2025 relating to REGENXBIO Inc.’s financial results.

 

 

 

99.2

 

Joint press release dated August 7, 2025.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

REGENXBIO INC.

 

 

 

 

Date:

August 7, 2025

By:

/s/ Patrick J. Christmas II

 

 

 

Patrick J. Christmas II
Executive Vice President, Chief Strategy & Legal Officer

 


FAQ

How many Spirit Aviation shares does M&G Plc own?

M&G reports beneficial ownership of 1,835,681 common shares.

What percentage of Spirit Aviation's outstanding stock does this represent?

The stake equals 7.09 % of the issuer’s outstanding common shares.

Does M&G have shared voting or dispositive power?

No. The filing shows sole voting and dispositive power; shared power is zero.

Is this an activist position?

The Schedule 13G is filed under Rule 13d-1(b) with a passive intent certification, indicating non-activist ownership.

Why did M&G have to file a Schedule 13G?

SEC rules require any person owning over 5 % of a U.S. company’s class of shares to file within 45 days; M&G crossed that threshold.
Regenxbio

NASDAQ:RGNX

RGNX Rankings

RGNX Latest News

RGNX Latest SEC Filings

RGNX Stock Data

417.72M
46.49M
7.69%
88.46%
12.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
ROCKVILLE